Alu insertion/deletion of ACE gene polymorphism might not affect significantly the serum bradykinin level in hypertensive patients taking ACE inhibitors

Widodo, Widodo and Wisnasari, Shila and Saifur Rohman, Mohammad and Yunita, Lowry and Lukitasari, Mifetika and Nuril, Maulidiyatun and Holil, Kholifah and Purwaningroom, Dian Laila (2017) Alu insertion/deletion of ACE gene polymorphism might not affect significantly the serum bradykinin level in hypertensive patients taking ACE inhibitors. Egyptian Journal of Medical Human Genetics, 18 (2). pp. 187-191. ISSN 11108630

[img]
Preview
Text (full text)
2582.pdf - Published Version

Download (953kB) | Preview
Full text available at: http://doi.org/10.1016/j.ejmhg.2016.08.001

Abstract

Background Angiotensin I-converting enzyme (ACE) has two homologous catalytic domains, the N- and C-domains. Our previous study suggested that Alu insertion (I allele) in the intron 16 of ACE resulted in premature codon termination. The I allele has only one active site in the N-domain while the Alu deletion (D allele) still has two active sites of ACE. Therefore the effect of I/D polymorphism of ACE on the enzyme's ability to catalyse bradykinin is still not widely known. Aims This study aimed to examine the serum bradykinin level in hypertensive patients with I/D polymorphism of ACE, who were treated with ACE inhibitor. Subjects and methods The serum bradykinin and I/D polymorphism have been detected in 64 hypertensive patients taking ACE inhibitor (lisinopril or captopril) for at least eight weeks with good medication adherence. The binding affinity of ACE with its receptor was calculated by molecular docking. Results The findings show that genotype II is more frequent in the population the researchers observed (53.12%) compared to ID (23.44%) and DD (23.44%) variances. On the other hand, the bradykinin level is not affected by genotype of the ACE genes on the population. Bradykinin increases in patients with genotype II who are given captopril, but decreases in patients treated with lisinopril. Nevertheless, there is no statistically significant difference. Conclusion This study suggests that the polymorphism might not significantly affect the serum bradykinin level in hypertensive patients taking ACE inhibitors.

Item Type: Journal Article
Keywords: angiotensin I; bradykinin; captopril; dipeptidyl carboxypeptidase; lisinopril, Alu sequence; amino terminal sequence; Article; binding affinity; carboxy terminal sequence; genetic polymorphism; genotype; human; hypertension; indel mutation; major clinical study; medication compliance; molecular docking; protein blood level
Divisions: Faculty of Mathematics and Sciences > Department of Biology
Depositing User: Heni Kurnia Ningsih
Date Deposited: 28 May 2018 03:14

Downloads

Downloads per month over past year

Origin of downloads

Actions (login required)

View Item View Item